Evidence map›Paper›PMID 41978941›Full record

ArticleEuropean journal of haematology2026

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Dörfel, Jörg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nadine KutschDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-9559-8575
Rudy LigtvoetDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-6546-0911
Sandra RobrechtDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
Hartmut LindePractice for Blood and Cancer Diseases, Potsdam, Germany.
Thomas IllmerPractice for Hematology and Oncology, Dresden, Germany.
Steffen DörfelOncozentrum, Dresden, Freiberg, Meißen, Germany.
Jörg LipkePractice for Hematology and Oncology, Dortmund, Germany.
Ali AldaoudPractice for Hematology and Oncology, Würzburg, Germany.
Rudolf SchlagPractice for Hematology and Oncology, Würzburg, Germany.
Jolanta DenglerPractice for Oncology, Heilbronn, Germany.
Othman Al-SawafDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-9895-0570
Petra LangerbeinsDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
Paula CramerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
Michael HallekDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
Barbara EichhorstDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
Kirsten FischerDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.
Anna FinkDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence. Venetoclax was administered as first-line treatment in 152 of 274 patients (55.5%). After a median observation time of 14 months from the start of the first documented venetoclax treatment, the 1-year event-free survival (EFS) was 82.1% and the 1-year overall survival (OS) was 94.2%. The 1-year OS was 96.3% when venetoclax was given as first-line treatment versus 92.1% when given for the first time in a later therapy line (HR 0.38, 95% CI 0.14-1.05). In the BTKi cohort, 351 of 888 patients (39.5%) received a BTKi as first-line treatment. The median observation time was 34 months from the start of the first documented BTKi treatment, with a 3-year EFS of 32.4% and a 3-year OS of 78.5%. The 3-year OS for a BTKi in first-line was 87.9% compared to 73.8% in a later therapy line (HR 0.43, 95% CI 0.30-0.61). Our analysis suggests better survival outcomes when these agents are used as first-line therapy with the caveat that patients treated in later therapy lines typically exhibit more advanced disease and a poorer general condition.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2AdenineAdultAgedAged, 80 and overBenzamidesBridged Bicyclo Compounds, HeterocyclicFemaleHumansMaleMiddle AgedPiperidinesacalabrutinibAdenineAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBCL2 protein, humanBenzamidesBridged Bicyclo Compounds, HeterocyclicBTK protein, humanibrutinibPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2PyrazinesSulfonamidesvenetoclax

Identifiers

PMID41978941
PMCPMC13326761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.